Bushu and Suzuken team up to support manufacturers eyeing up Japanese market
The new business alliance will support new product launches for specialty pharmaceutical manufacturers looking to enter the Japanese market
Contract manufacturer Bushu Pharmaceuticals has signed a business agreement with Suzuken, to offer support services for new product launches for specialty pharmaceutical manufacturers looking to enter the Japanese market.
The alliance between the two firms will establish a one-stop logistics centre in Soka City, Saitama Prefecture, for manufacturing operations and general logistics.
Bushu Pharma will be able to conduct contract manufacturing operations from the site and the two companies will work together to offer one-stop services for specialty pharmaceuticals, including marketing authorisation holder/drug approval holder consulting, import, inspection, manufacturing, storage (manufacturer logistics), wholesale distribution, post-marketing survey, and patient support.
In addition, through the use of the Cubixx specialty drug traceability system, developed by Suzuken, Bushu Pharma will provide delivery of products all the way to patients.
The alliance also enables Bushu Pharma to utilize the 1,465-m2 cold storage area newly established within the Kazo Pharmaceutical Joint Distribution Center of Chuo Unyu, a subsidiary of Suzuken. The area will make it possible for Bushu Pharma to carry out contract manufacturing centered on secondary packaging such as inspection, labelling, and packaging.
Furthermore, the two companies, including S.D. Collaboration Co. (another Suzuken subsidiary), have also started joint proposal sales efforts to specialty pharmaceutical manufacturers who are planning to enter the Japanese market, led through Bushu Pharma’s US office in North Carolina.
In recent years, the number of innovative specialty pharmaceuticals on the market that require strict temperature, inventory, and security control has been increasing, as has the number of pharmaceutical manufacturers looking to introduce these products to Japan. These manufacturers, however, frequently lack the required assets such as manufacturing plants, distribution centres and networks necessary to enter the Japanese market with minimal resources and, therefore, must outsource these functions.
Suzuken possesses a distribution network in Japan that can support the international transportation of specialty pharmaceuticals. Bushu Pharma has been contract manufacturing in Japan for more than 20 years, holds GMP certifications from all over the world, and has a track record of exporting to more than 43 countries.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.